Industry Trends: By The Numbers

Compiled by Cari Kraft, Jacobs Management Group, Inc.

258

Number of vaccines under development for many conditions.

Industry organization PhRMA reports that 258 vaccines are in development in the US, including 108 for cancer, 125 for infectious diseases, 14 for allergies, and two for Alzheimer’s disease. Additionally, there are more than 70 for Covid-19 in the global research pipeline, including six now in human clinical trials.

Source: PhRMA, Biopharmaceutical Companies are Researching and Developing Nearly 260 Vaccines, April 2020 15

Number of countries that ship 86% of all drugs

Only 15 countries are producing and exporting 86.2% of all medicines, according to 2019 figures. Germany (14.5%), Switzerland (12.2%), The Netherlands (7.9%), Belgium (7.4%), France (6.8%) and Italy (6.3%) all lead the US, which exports 6.2%, valued at $24.3B. Fastest growing are Denmark, Netherlands, Italy and Switzerland. Source: World’s Top Experts, Drugs and Medicine Exports by Country, August, 2020 48

Number of novelty drugs approved by CDER in 2019

The Center for Drug Evaluation and Research (CDER), an FDA-regulated division that deals with drug approvals, approved a record number of novelty drugs in 2019. Novelty drugs are new molecular entities that have the potential to treat diseases with a new pharmacological mechanism. Twenty of these products are considered first-in-class drugs. Some of the new medicines treat conditions such as postpartum depression (brexanolone), or metastatic bladder cancer (erdafitinib). Source: FDA, New Drug Approvals 2019, January 2020

80%

Share of drug market held by branded medicines in US

In the United States, approximately $511B was spent on medicines in 2019. Sales of brand name drugs account for 80 percent of the total, with around 20 percent spent on generic drugs. Sales of branded generics accounted for 8.8 percent and unbranded generics and 11.2 percent. Source: Statista, Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2019, August 2020

52%

of telehealth users report barriers

Although telehealth services are increasingly being used, largely in response to the Covid-19 crisis, there are still problems with access. Overall customer satisfaction is 860 on a 1000-point scale, but 52% of users say that they experienced limited services (24%), confusing tech requirements (17%), and lack of awareness of cost (15%). In addition,

Number of doctor visits that will be

as 77% among people with chronic

35% said they had a problem (such as audio issues) during a visit. Source: J.D. Power 2020 U.S. Telehealth Satisfaction Survey

22%

Amount of total global pharma represented by emerging markets

Emerging markets have grown steadily between 2014 and 2019, from 20% to 22% of worldwide sales. The US has also grown in that period, from 45% to 48%, while Europe has fallen from 22% to 19%, and other markets have decreased from 13% to 11%. Source: Statista, Distribution of the total global pharmaceutical market sales from 2014 to 2019, by 20%

conducted by telehealth in 2020

Telehealth visits in the US will reach 20% of the total in 2020. The number of people reporting at least one telehealth visit has grown by 57%, and as much submarket, April 2020

illnesses. The number of physicians listing telemedicine as a skill has increased 20% year-over-year since 2017. Source: Doximity, 2020 State of Telemedicine Report